The negative ANSA-RAD trial, when contrasted with the positive STAMPEDE trial, demonstrates that patient selection is paramount in adjuvant therapy. The difference in outcomes was driven by risk definition, not the drug. This reinforces that "negative" trials are clinically vital for defining which patient populations do not benefit, preventing widespread overtreatment.

An analysis of EMERALD and LEAP trial criteria against real-world HCC cases reveals that a majority of complex patients (e.g., multifocal, large tumors) who could most benefit from combination therapies were ineligible, cautioning clinicians against broad application of trial results.

The DYNAMIC trial disappointingly showed that intensifying adjuvant chemotherapy for high-risk, ctDNA-positive stage 3 colorectal cancer patients does not improve outcomes. This suggests that for these tumors, underlying biology dictates recurrence more strongly than the aggressiveness of chemotherapy.

Given that standard therapies for metastatic pancreatic cancer are not curative, leading oncologists argue that clinical trials should be the primary consideration for all eligible patients. Standard chemotherapy regimens are viewed as fallback options. This approach frames trials as the best path to advancing care, not an experimental last resort.

Despite the success of ctDNA-guided de-escalation in Stage II disease, the DYNAMIC-3 trial in Stage III patients showed that ctDNA-negative patients had worse outcomes with de-escalated therapy. This serves as a critical warning against this de-escalation strategy in higher-risk patients for now.

The unexpected negative result of the PERSEVERA trial testing jiridestrant in the first-line metastatic setting serves as a humbling lesson. It shows that theoretical biological advantages do not always translate to clinical benefit and that the current standard of care is an exceptionally high bar to surpass.

Despite the excellent prognosis associated with a negative post-operative MRD test, oncologists are not yet comfortable omitting adjuvant chemotherapy for younger, high-risk stage II colon cancer patients. The current data is not considered sufficient to justify de-escalation based on a negative ctDNA result alone outside of a clinical trial setting.

The KIDO 905 trial revealed high rates of adverse events even in the control arm receiving only surgery. This suggests the invasive procedure itself is a major source of patient harm, paving the way for future surgery-free regimens if systemic treatments like EVP prove sufficiently effective.

For every 10 Stage III patients receiving adjuvant chemo, 5 are already cured by surgery and 2-3 will recur regardless. This means therapy only benefits 2-3 patients, leading to significant overtreatment for the majority who endure toxicity without benefit.